The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Papillary Thyroid Carcinoma Treatment Market Research Report 2024
Synopsis
Papillary cancer and its variants. Most cancers are treated with removal of the thyroid gland (thyroidectomy), although small tumors that have not spread outside the thyroid gland may be treated by just removing the side of the thyroid containing the tumor (lobectomy).
Global Papillary Thyroid Carcinoma Treatment market is projected to reach US$ 1913.7 million in 2029, increasing from US$ 1300 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Papillary Thyroid Carcinoma Treatment market research.
The global papillary thyroid carcinoma (PTC) treatment market refers to the market for therapeutic interventions and management strategies aimed at treating papillary thyroid carcinoma, the most common type of thyroid cancer. PTC arises from the follicular cells of the thyroid gland and is characterized by the formation of abnormal papillary structures.
The market for PTC treatment is driven by several factors, including the increasing incidence of thyroid cancer, advancements in diagnostic techniques, and growing awareness about the disease. The most common treatment approaches for PTC include surgery, radioactive iodine therapy, and thyroid hormone replacement therapy.
Surgery is the primary treatment option for PTC, typically involving total or partial thyroidectomy to remove the cancerous tissue. Radioactive iodine therapy is often administered after surgery to eliminate any remaining cancer cells. Thyroid hormone replacement therapy is given to restore the normal thyroid hormone levels in the body after thyroidectomy.
Geographically, North America holds a significant share in the global PTC treatment market, primarily due to factors such as well-established healthcare infrastructure, high awareness levels, and the availability of advanced treatment options. Europe is another prominent market, driven by factors such as the rising incidence of thyroid cancer and increasing investments in research and development.
Asia-Pacific is witnessing significant growth in the PTC treatment market, attributed to factors such as the increasing prevalence of thyroid disorders, improving healthcare infrastructure, and rising healthcare expenditure in countries like China and India.
Key players in the global PTC treatment market include AbbVie Inc., AstraZeneca plc, Eisai Co., Ltd., Bristol Myers Squibb, and Sanofi, among others. These companies focus on developing innovative therapies, conducting clinical trials, and strategic collaborations to improve treatment outcomes and expand their market presence.
However, challenges in the PTC treatment market include the potential for recurrence, adverse effects of treatment, and the need for individualized treatment approaches based on patient-specific characteristics.
In summary, the global papillary thyroid carcinoma treatment market is driven by factors such as the increasing incidence of thyroid cancer, advancements in treatment options, and growing awareness about the disease. North America currently leads the market, but Asia-Pacific is witnessing rapid growth. Key players in the market continue to invest in research and development to enhance treatment efficacy and address the evolving needs of PTC patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Papillary Thyroid Carcinoma Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Roche Holding AG
Thermo Fisher Scientific Inc
Siemens Healthineers
Bio-Rad Laboratories
Agilent Technologies
Illumina
Hologic
Leica Biosystems Nussloch GmbH
FUJIFILM Holdings Corporation
Merck KGaA
Beckman Coulter
Randox Laboratories
Segment by Type
Surgery
Iodine Therapy
Thyroxin Treatment
External Radiotherapy
Chemotherapy
Other
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Papillary Thyroid Carcinoma Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Papillary cancer and its variants. Most cancers are treated with removal of the thyroid gland (thyroidectomy), although small tumors that have not spread outside the thyroid gland may be treated by just removing the side of the thyroid containing the tumor (lobectomy).
Global Papillary Thyroid Carcinoma Treatment market is projected to reach US$ 1913.7 million in 2029, increasing from US$ 1300 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Papillary Thyroid Carcinoma Treatment market research.
The global papillary thyroid carcinoma (PTC) treatment market refers to the market for therapeutic interventions and management strategies aimed at treating papillary thyroid carcinoma, the most common type of thyroid cancer. PTC arises from the follicular cells of the thyroid gland and is characterized by the formation of abnormal papillary structures.
The market for PTC treatment is driven by several factors, including the increasing incidence of thyroid cancer, advancements in diagnostic techniques, and growing awareness about the disease. The most common treatment approaches for PTC include surgery, radioactive iodine therapy, and thyroid hormone replacement therapy.
Surgery is the primary treatment option for PTC, typically involving total or partial thyroidectomy to remove the cancerous tissue. Radioactive iodine therapy is often administered after surgery to eliminate any remaining cancer cells. Thyroid hormone replacement therapy is given to restore the normal thyroid hormone levels in the body after thyroidectomy.
Geographically, North America holds a significant share in the global PTC treatment market, primarily due to factors such as well-established healthcare infrastructure, high awareness levels, and the availability of advanced treatment options. Europe is another prominent market, driven by factors such as the rising incidence of thyroid cancer and increasing investments in research and development.
Asia-Pacific is witnessing significant growth in the PTC treatment market, attributed to factors such as the increasing prevalence of thyroid disorders, improving healthcare infrastructure, and rising healthcare expenditure in countries like China and India.
Key players in the global PTC treatment market include AbbVie Inc., AstraZeneca plc, Eisai Co., Ltd., Bristol Myers Squibb, and Sanofi, among others. These companies focus on developing innovative therapies, conducting clinical trials, and strategic collaborations to improve treatment outcomes and expand their market presence.
However, challenges in the PTC treatment market include the potential for recurrence, adverse effects of treatment, and the need for individualized treatment approaches based on patient-specific characteristics.
In summary, the global papillary thyroid carcinoma treatment market is driven by factors such as the increasing incidence of thyroid cancer, advancements in treatment options, and growing awareness about the disease. North America currently leads the market, but Asia-Pacific is witnessing rapid growth. Key players in the market continue to invest in research and development to enhance treatment efficacy and address the evolving needs of PTC patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Papillary Thyroid Carcinoma Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Roche Holding AG
Thermo Fisher Scientific Inc
Siemens Healthineers
Bio-Rad Laboratories
Agilent Technologies
Illumina
Hologic
Leica Biosystems Nussloch GmbH
FUJIFILM Holdings Corporation
Merck KGaA
Beckman Coulter
Randox Laboratories
Segment by Type
Surgery
Iodine Therapy
Thyroxin Treatment
External Radiotherapy
Chemotherapy
Other
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Papillary Thyroid Carcinoma Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Papillary Thyroid Carcinoma Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Surgery
1.2.3 Iodine Therapy
1.2.4 Thyroxin Treatment
1.2.5 External Radiotherapy
1.2.6 Chemotherapy
1.2.7 Other
1.3 Market by Application
1.3.1 Global Papillary Thyroid Carcinoma Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Papillary Thyroid Carcinoma Treatment Market Perspective (2018-2029)
2.2 Papillary Thyroid Carcinoma Treatment Growth Trends by Region
2.2.1 Global Papillary Thyroid Carcinoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Papillary Thyroid Carcinoma Treatment Historic Market Size by Region (2018-2023)
2.2.3 Papillary Thyroid Carcinoma Treatment Forecasted Market Size by Region (2024-2029)
2.3 Papillary Thyroid Carcinoma Treatment Market Dynamics
2.3.1 Papillary Thyroid Carcinoma Treatment Industry Trends
2.3.2 Papillary Thyroid Carcinoma Treatment Market Drivers
2.3.3 Papillary Thyroid Carcinoma Treatment Market Challenges
2.3.4 Papillary Thyroid Carcinoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Papillary Thyroid Carcinoma Treatment Players by Revenue
3.1.1 Global Top Papillary Thyroid Carcinoma Treatment Players by Revenue (2018-2023)
3.1.2 Global Papillary Thyroid Carcinoma Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Papillary Thyroid Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Papillary Thyroid Carcinoma Treatment Revenue
3.4 Global Papillary Thyroid Carcinoma Treatment Market Concentration Ratio
3.4.1 Global Papillary Thyroid Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Papillary Thyroid Carcinoma Treatment Revenue in 2022
3.5 Papillary Thyroid Carcinoma Treatment Key Players Head office and Area Served
3.6 Key Players Papillary Thyroid Carcinoma Treatment Product Solution and Service
3.7 Date of Enter into Papillary Thyroid Carcinoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Papillary Thyroid Carcinoma Treatment Breakdown Data by Type
4.1 Global Papillary Thyroid Carcinoma Treatment Historic Market Size by Type (2018-2023)
4.2 Global Papillary Thyroid Carcinoma Treatment Forecasted Market Size by Type (2024-2029)
5 Papillary Thyroid Carcinoma Treatment Breakdown Data by Application
5.1 Global Papillary Thyroid Carcinoma Treatment Historic Market Size by Application (2018-2023)
5.2 Global Papillary Thyroid Carcinoma Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Papillary Thyroid Carcinoma Treatment Market Size (2018-2029)
6.2 North America Papillary Thyroid Carcinoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Papillary Thyroid Carcinoma Treatment Market Size by Country (2018-2023)
6.4 North America Papillary Thyroid Carcinoma Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Papillary Thyroid Carcinoma Treatment Market Size (2018-2029)
7.2 Europe Papillary Thyroid Carcinoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Papillary Thyroid Carcinoma Treatment Market Size by Country (2018-2023)
7.4 Europe Papillary Thyroid Carcinoma Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Papillary Thyroid Carcinoma Treatment Market Size (2018-2029)
8.2 Asia-Pacific Papillary Thyroid Carcinoma Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Papillary Thyroid Carcinoma Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Papillary Thyroid Carcinoma Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Papillary Thyroid Carcinoma Treatment Market Size (2018-2029)
9.2 Latin America Papillary Thyroid Carcinoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Papillary Thyroid Carcinoma Treatment Market Size by Country (2018-2023)
9.4 Latin America Papillary Thyroid Carcinoma Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Papillary Thyroid Carcinoma Treatment Market Size (2018-2029)
10.2 Middle East & Africa Papillary Thyroid Carcinoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Papillary Thyroid Carcinoma Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Papillary Thyroid Carcinoma Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Papillary Thyroid Carcinoma Treatment Introduction
11.1.4 Abbott Laboratories Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Roche Holding AG
11.2.1 Roche Holding AG Company Detail
11.2.2 Roche Holding AG Business Overview
11.2.3 Roche Holding AG Papillary Thyroid Carcinoma Treatment Introduction
11.2.4 Roche Holding AG Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.2.5 Roche Holding AG Recent Development
11.3 Thermo Fisher Scientific Inc
11.3.1 Thermo Fisher Scientific Inc Company Detail
11.3.2 Thermo Fisher Scientific Inc Business Overview
11.3.3 Thermo Fisher Scientific Inc Papillary Thyroid Carcinoma Treatment Introduction
11.3.4 Thermo Fisher Scientific Inc Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.3.5 Thermo Fisher Scientific Inc Recent Development
11.4 Siemens Healthineers
11.4.1 Siemens Healthineers Company Detail
11.4.2 Siemens Healthineers Business Overview
11.4.3 Siemens Healthineers Papillary Thyroid Carcinoma Treatment Introduction
11.4.4 Siemens Healthineers Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.4.5 Siemens Healthineers Recent Development
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Detail
11.5.2 Bio-Rad Laboratories Business Overview
11.5.3 Bio-Rad Laboratories Papillary Thyroid Carcinoma Treatment Introduction
11.5.4 Bio-Rad Laboratories Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.5.5 Bio-Rad Laboratories Recent Development
11.6 Agilent Technologies
11.6.1 Agilent Technologies Company Detail
11.6.2 Agilent Technologies Business Overview
11.6.3 Agilent Technologies Papillary Thyroid Carcinoma Treatment Introduction
11.6.4 Agilent Technologies Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.6.5 Agilent Technologies Recent Development
11.7 Illumina
11.7.1 Illumina Company Detail
11.7.2 Illumina Business Overview
11.7.3 Illumina Papillary Thyroid Carcinoma Treatment Introduction
11.7.4 Illumina Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.7.5 Illumina Recent Development
11.8 Hologic
11.8.1 Hologic Company Detail
11.8.2 Hologic Business Overview
11.8.3 Hologic Papillary Thyroid Carcinoma Treatment Introduction
11.8.4 Hologic Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.8.5 Hologic Recent Development
11.9 Leica Biosystems Nussloch GmbH
11.9.1 Leica Biosystems Nussloch GmbH Company Detail
11.9.2 Leica Biosystems Nussloch GmbH Business Overview
11.9.3 Leica Biosystems Nussloch GmbH Papillary Thyroid Carcinoma Treatment Introduction
11.9.4 Leica Biosystems Nussloch GmbH Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.9.5 Leica Biosystems Nussloch GmbH Recent Development
11.10 FUJIFILM Holdings Corporation
11.10.1 FUJIFILM Holdings Corporation Company Detail
11.10.2 FUJIFILM Holdings Corporation Business Overview
11.10.3 FUJIFILM Holdings Corporation Papillary Thyroid Carcinoma Treatment Introduction
11.10.4 FUJIFILM Holdings Corporation Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.10.5 FUJIFILM Holdings Corporation Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Detail
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Papillary Thyroid Carcinoma Treatment Introduction
11.11.4 Merck KGaA Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.11.5 Merck KGaA Recent Development
11.12 Beckman Coulter
11.12.1 Beckman Coulter Company Detail
11.12.2 Beckman Coulter Business Overview
11.12.3 Beckman Coulter Papillary Thyroid Carcinoma Treatment Introduction
11.12.4 Beckman Coulter Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.12.5 Beckman Coulter Recent Development
11.13 Randox Laboratories
11.13.1 Randox Laboratories Company Detail
11.13.2 Randox Laboratories Business Overview
11.13.3 Randox Laboratories Papillary Thyroid Carcinoma Treatment Introduction
11.13.4 Randox Laboratories Revenue in Papillary Thyroid Carcinoma Treatment Business (2018-2023)
11.13.5 Randox Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
